McKenzie R - Search Results

1

Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL. Carpenter CM, et al. Among authors: mckenzie r. Vaccine. 2006 May 1;24(18):3709-18. doi: 10.1016/j.vaccine.2005.07.022. Epub 2005 Jul 26. Vaccine. 2006. PMID: 16153753

2

Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA. McKenzie R, et al. Infect Immun. 2006 Feb;74(2):994-1000. doi: 10.1128/IAI.74.2.994-1000.2006. Infect Immun. 2006. PMID: 16428745 Free PMC article. Clinical Trial.

3

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM. McKenzie R, et al. Vaccine. 2007 May 4;25(18):3684-91. doi: 10.1016/j.vaccine.2007.01.043. Epub 2007 Jan 23. Vaccine. 2007. PMID: 17313998 Clinical Trial.

4

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL. McKenzie R, et al. Vaccine. 2008 Aug 26;26(36):4731-9. doi: 10.1016/j.vaccine.2008.06.064. Epub 2008 Jul 9. Vaccine. 2008. PMID: 18602960 Clinical Trial.

5

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Feller AJ, McKenzie R, Taylor DN, Woods CC, Grahek SL, Islam D, Venkatesan MM, Hale TL, Bourgeois AL. Feller AJ, et al. Among authors: mckenzie r. Vaccine. 2011 Nov 3;29(47):8487-9. doi: 10.1016/j.vaccine.2011.09.030. Epub 2011 Sep 20. Vaccine. 2011. PMID: 21939714 Free PMC article.

6

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL. McKenzie R, et al. Vaccine. 2006 May 1;24(18):3735-45. doi: 10.1016/j.vaccine.2005.07.014. Epub 2005 Jul 21. Vaccine. 2006. PMID: 16095766 Clinical Trial.

7

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL. McKenzie R, et al. Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16. Vaccine. 2008. PMID: 18468742 Clinical Trial.

8

Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19.

McKenzie R, Porter CK, Cantrell JA, Denearing B, O'Dowd A, Grahek SL, Sincock SA, Woods C, Sebeny P, Sack DA, Tribble DR, Bourgeois AL, Savarino SJ. McKenzie R, et al. J Infect Dis. 2011 Jul 1;204(1):60-4. doi: 10.1093/infdis/jir220. J Infect Dis. 2011. PMID: 21628659 Free PMC article.

9

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, DeNearing B, Steinsland H, Tribble DR, Bourgeois AL. Porter CK, et al. Among authors: mckenzie r. PLoS One. 2016 Mar 3;11(3):e0149358. doi: 10.1371/journal.pone.0149358. eCollection 2016. PLoS One. 2016. PMID: 26938983 Free PMC article.

10

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN. Kirkpatrick BD, et al. Among authors: mckenzie r. Vaccine. 2006 Jan 12;24(2):116-23. doi: 10.1016/j.vaccine.2005.08.008. Epub 2005 Aug 18. Vaccine. 2006. PMID: 16140433 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

785 results

Search Page